U.S. markets closed

Immunocore Holdings plc (IMCR)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
70.45-0.52 (-0.73%)
Al cierre: 04:00PM EST
72.00 +1.55 (+2.20%)
Fuera de horario: 08:00PM EST

Immunocore Holdings plc

92 Park Drive
Milton Park
Abingdon OX14 4RY
United Kingdom
44 12 3543 8600
https://www.immunocore.com

Sector(es)Healthcare
IndustriaBiotechnology
Empleados a tiempo completo408

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Dr. Bahija Jallal Ph.D.CEO & Director1.42MN/D1962
Mr. Brian R. Di Donato M.B.A.CFO & Head of StrategyN/DN/D1967
Ms. Annelise Vuidepot Ph.D.CTO and Head of Pipeline & Platform ResearchN/DN/DN/D
Clayton RobertsonHead of Investor RelationsN/DN/DN/D
Ms. Lily Margaret HepworthGeneral Counsel & Company SecretaryN/DN/DN/D
Ms. Amy Judge-PreinChief Compliance OfficerN/DN/DN/D
Mr. Sébastien DesprezHead of CommunicationsN/DN/DN/D
Ms. Tina St. LegerChief Human Resources Officer & DirectorN/DN/D1968
Dr. David Berman M.D., Ph.D.Head of Research & DevelopmentN/DN/D1971
Ms. Debra NielsenChief of StaffN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also developing other programs for oncology comprise tebentafusp that is in Phase 2/3 clinical trial in patients with advanced melanoma; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising cutaneous melanoma, ovarian, non-small cell lung cancer, and endometrial; IMC-T119C for multiple solid tumor cancers; IMC-P115C for multiple solid tumor cancers; and IMC-R117C, which is for a range of tumors, including colorectal, gastro-esophageal, and pancreatic cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in Phase 1 clinical trial for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Gestión corporativa

La calificación ISS Governance QuickScore de Immunocore Holdings plc a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.